Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models

Immune checkpoint inhibitors have been found to be effective in metastatic MSI-high colorectal cancers (CRC), however, have no efficacy in microsatellite stable (MSS) cancers, which comprise the majority of mCRC cases. Cabozantinib is a small molecule multi-tyrosine kinase inhibitor that is FDA appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Julie, Leal, Alexis D., Marín-Jiménez, Juan A., Hartman, Sarah J., Shulman, Jeremy, Navarro, Natalie M., Lewis, Matthew S., Capasso, Anna, Bagby, Stacey M., Yacob, Bethlehem W., MacBeth, Morgan, Freed, Brian M., Eckhardt, S. Gail, Jordan, Kimberly, Blatchford, Patrick J., Pelanda, Roberta, Lieu, Christopher H., Messersmith, Wells A., Pitts, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676436/
https://www.ncbi.nlm.nih.gov/pubmed/36419897
http://dx.doi.org/10.3389/fonc.2022.877635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676436/
https://www.ncbi.nlm.nih.gov/pubmed/36419897
http://dx.doi.org/10.3389/fonc.2022.877635

Ejemplares similares